Search Result

Results for "

kidney fibrosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) EGFR (1) Epigenetic Reader Domain (1) Free Fatty Acid Receptor (1) GPR84 (1) Histone Methyltransferase (2) Keap1-Nrf2 (1) MAP3K (1) MMP (1) NF-κB (1) Procollagen C Proteinase (1) Src (1) STAT (1) TGF-beta/Smad (2)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (7) Metabolic Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Targets Recommended: CFTR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P5314

OK2	EGFR STAT	Others
OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research .

HY-156430

MMP-7-IN-3	MMP	Cancer
MMP-7-IN-3 is a potent and selective inhibitor of MMP-7. MMP-7-IN-3 suppresses kidney fibrosis progression in a mouse model with unilateral ureteral obstruction .

HY-155657

BT424	Src	Inflammation/Immunology
BT424 is a specific HCK inhibitor. BT424 can regulate macrophage activation and autophagy in vitro. BT424 ameliorates inflammation and kidney fibrosis in UUO model .

HY-18627A

PFI-2 hydrochloride 5+ Cited Publications (R)-PFI-2 hydrochloride	Histone Methyltransferase	Infection Inflammation/Immunology Cancer
PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride is a potent and selective SET domain containing lysine methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC₅₀ value of 2.0 nM and (S)-PFI-2 shows inhibiting activity with IC₅₀ value of 1.0 μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis .

HY-18938

Selonsertib Maximum Cited Publications 15 Publications Verification GS-4997	MAP3K Apoptosis	Cancer
Selonsertib (GS-4997), an orally bioavailable, selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC₅₀ of 8.3, has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis.

HY-13102

UK-383367	Procollagen C Proteinase	Others
UK-383367 is an orally available pro-collagen C-protease inhibitor (BMP-1) with an IC₅₀ value of 44 nM. UK-383367 can reduce renal fibrosis and inflammation in chronic kidney disease (CKD) and may be used to study postoperative skin scarring .

HY-112671

CDDO-dhTFEA RTA dh404	Keap1-Nrf2 NF-κB	Cardiovascular Disease Inflammation/Immunology
CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB . CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats .

HY-P99020

Fresolimumab 1 Publications Verification GC1008	TGF-beta/Smad	Metabolic Disease Inflammation/Immunology Cancer
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab radiolabeled with ⁸⁹Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .

HY-18627

PFI-2 (R)-PFI-2	Histone Methyltransferase	Infection Inflammation/Immunology Cancer
PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride is a potent and selective SET domain containing lysine methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC₅₀ value of 2.0 nM and (S)-PFI-2 shows inhibiting activity with IC₅₀ value of 1.0 μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis .

HY-144236

ZLD2218	Epigenetic Reader Domain	Others
Considerable studies confirmed that BRD4 inhibition ameliorated kidney injury and fibrosis ，and ZLD2218 exhibited the most potent inhibitory activity against BRD4, with the IC₅₀ value of 107 nM

HY-100775A

Fezagepras Setogepram; PBI-4050	Free Fatty Acid Receptor GPR84	Metabolic Disease Inflammation/Immunology
Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras decreases renal, liver and pancreatic fibrosis . Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .

HY-W803134

(E/Z)-SIS3 free base	TGF-beta/Smad	Inflammation/Immunology
E/Z-SIS3 free base exhibits an inhibitory efficacy against smad3, exhibits an anti-fibrotic and anti-inflammatory effect through a TGF-β/smad3 signaling pathway .

Cat. No.	Product Name

HY-L185

Anti-Fibrosis Compound Library	1,648 compounds
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening. MCE contains 1,648 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Anti-Fibrosis Compound Library

1,648 compounds

Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening.

MCE contains 1,648 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Cat. No.	Product Name	Target	Research Area

HY-P5314

OK2	EGFR STAT	Others
OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research .

HY-156430

MMP-7-IN-3	MMP	Cancer
MMP-7-IN-3 is a potent and selective inhibitor of MMP-7. MMP-7-IN-3 suppresses kidney fibrosis progression in a mouse model with unilateral ureteral obstruction .

Cat. No.	Product Name	Target	Research Area

HY-P99020

Fresolimumab 1 Publications Verification GC1008	TGF-beta/Smad	Metabolic Disease Inflammation/Immunology Cancer
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab radiolabeled with ⁸⁹Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.